Furthermore, multiple in vitro and in vivo evidences has shown that NRAS mutated myeloma and/or leukemic cells are resistant to KRASG12C-targeted small molecules (Welsch et al., 2017; Janes et al., 2018; Canon et al., 2019; Hallin et al., 2020), indicating the specificity of NRAS targeting. Here, NRAS is linked to plasma cell myeloma.